Circularly permutated F1; 100% survival in mice
Tel Aviv University and the Israel Institute for Biological Research, which sits under the Prime Minister’s Office. One mRNA construct for a redesigned F1 capsule antigen, inside a lipid nanoparticle. A 2023 mouse study reported complete survival after a single dose in a bubonic model. It has not entered human trials. There is no listed company on the programme.
Preclinical · bubonic. Phase 3 is empty here, as it is for every programme in the set.
A mark at 2023. Labelled “2023” on the briefing. Not a forecast.
Analyst card
- Bubonic mouse model. One dose. Pneumonic and septicemic challenge are not in the 2023 report used here.
- Not covered by design. The construct is F1 only, so an F1-negative strain has nothing for it to recognise. That challenge was not run.
- Lipid nanoparticle. No extra adjuvant named.
- A single dose. The injection site is not stated.
- mRNA in lipid nanoparticles. An ultra-cold requirement is not stated.
- Not reported. No time-to-protection figure is in the briefing.
- Plague only.
- The 2023 mouse paper reported complete survival in the bubonic model. Dose and LD50 are not restated here.
- Mouse data only. Not an Animal Rule file. No primate study is recorded.
Pipeline record
- Tel Aviv University and the Israel Institute for Biological Research, under the Prime Minister’s Office.
- One mRNA for a circularly permuted F1 capsule antigen, inside a lipid nanoparticle.
- A single dose.
- A 2023 mouse study reported complete survival in a bubonic model. Not in humans. No listed company.
News
Checking today’s headlines.
Latest intel
Checking Europe PMC.
PubMed
Checking today’s index.
- mRNA
Messenger RNA in lipid nanoparticles instructs cells to make plague antigens for a short time. Both programmes in this set are still preclinical.
- Israel — IIBR (Prime Minister's Office) + Tel Aviv Univ.
- Israel
- Bubonic · mice
- Preclinical · bubonic
- 2023
- F1